[REVISION HISTORY]
Glioblastoma treatment research advances
Updated 3 times since CLSTR started tracking revisions of this situation.
What changed
2026-08-06 04:55 UTC → 2026-08-06 09:21 UTC ·
added
removed
Recent glioblastoma research has focused on explored novel delivery methods and combination therapies. In late July 2026, the The University of Virginia introduced demonstrated a platform that uses using brain‑penetrating nanoparticles loaded with microRNA together with focused‑ultrasound‑induced microbubbles to transiently open the blood‑brain barrier and suppress multiple tumor‑driving genes. In the same period, UT Southwestern reported that pretreating glioblastoma cells with the EGFR inhibitor afatinib before temozolomide reduces MGMT‑mediated resistance, suggesting a sequential regimen could improve chemotherapy outcomes. A week later, UVA’s Focused Ultrasound Cancer Immunotherapy Center showed that gliomas are unusually susceptible to drug delivery via focused ultrasound, reinforcing the potential of blood‑brain‑barrier opening to enhance both existing and emerging therapeutics. As of early August 2026, no additional glioblastoma‑focused studies have been reported.
Versions
- 2026-08-06 09:21 UTC Glioblastoma treatment research advances
- 2026-08-06 04:55 UTC Glioblastoma treatment research advances
- 2026-08-05 17:02 UTC Glioblastoma treatment research advances
- 2026-08-05 07:05 UTC Glioblastoma treatment research advances
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.